These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15630668)

  • 1. Current role of antithrombotic agents in the treatment of acute coronary syndromes.
    Mukherjee D; Bates ER
    Semin Thromb Hemost; 2004 Dec; 30(6):627-32. PubMed ID: 15630668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.
    Lepor NE
    Rev Cardiovasc Med; 2007; 8 Suppl 3():S9-17. PubMed ID: 17917621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct thrombin inhibitors in cardiac disease.
    Weitz JI; Bates ER
    Cardiovasc Toxicol; 2003; 3(1):13-25. PubMed ID: 12668887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinician update: direct thrombin inhibitors in acute coronary syndromes.
    Wykrzykowska JJ; Kathiresan S; Jang IK
    J Thromb Thrombolysis; 2003 Feb; 15(1):47-57. PubMed ID: 14574076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where?
    Lincoff AM
    Am Heart J; 2003 Oct; 146(4 Suppl):S23-30. PubMed ID: 14564303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of thrombin inhibition during percutaneous coronary intervention.
    Wittkowsky AK
    Pharmacotherapy; 2002 Jun; 22(6 Pt 2):97S-104S. PubMed ID: 12064571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulants in acute coronary syndromes.
    Turpie AG
    Am J Cardiol; 1999 Sep; 84(5A):2M-6M. PubMed ID: 10505536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin inhibitors.
    Gurm HS; Bhatt DL
    Am Heart J; 2005 Jan; 149(1 Suppl):S43-53. PubMed ID: 15644793
    [No Abstract]   [Full Text] [Related]  

  • 9. [New antithrombotic drugs].
    Taliani MR; Agnelli G
    Recenti Prog Med; 1999 Feb; 90(2):86-93. PubMed ID: 10208099
    [No Abstract]   [Full Text] [Related]  

  • 10. The evolving role of direct thrombin inhibitors in acute coronary syndromes.
    Eikelboom J; White H; Yusuf S
    J Am Coll Cardiol; 2003 Feb; 41(4 Suppl S):70S-78S. PubMed ID: 12644344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
    Direct Thrombin Inhibitor Trialists' Collaborative Group
    Lancet; 2002 Jan; 359(9303):294-302. PubMed ID: 11830196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trials of conjunctive anticoagulant strategies in thrombolysis.
    Kleiman NS
    Coron Artery Dis; 1996 Jul; 7(7):508-15. PubMed ID: 8913678
    [No Abstract]   [Full Text] [Related]  

  • 13. New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?
    Esteve-Pastor MA; Hernández-Romero D; Valdés M; Marín F
    Molecules; 2016 Feb; 21(3):284. PubMed ID: 26927051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct thrombin inhibitors: appraisal of the antithrombotic/hemorrhagic balance.
    Verstraete M
    Thromb Haemost; 1997 Jul; 78(1):357-63. PubMed ID: 9198179
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of low-molecular-weight heparin in the management of acute coronary syndromes.
    Cohen M
    Curr Opin Cardiol; 2001 Nov; 16(6):384-9. PubMed ID: 11704710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current anticoagulation options in percutaneous intervention: designing patient-specific strategies.
    French MH; Faxon DP
    Rev Cardiovasc Med; 2002; 3(4):176-82. PubMed ID: 12556751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
    Stone GW; Bertrand M; Colombo A; Dangas G; Farkouh ME; Feit F; Lansky AJ; Lincoff AM; Mehran R; Moses JW; Ohman M; White HD
    Am Heart J; 2004 Nov; 148(5):764-75. PubMed ID: 15523305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-molecular-weight heparins : mechanisms, trials, and role in contemporary interventional medicine.
    Canales JF; Ferguson JJ
    Am J Cardiovasc Drugs; 2008; 8(1):15-25. PubMed ID: 18303934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiology.
    Ahrens I; Smith BK; Bode C; Peter K
    Expert Opin Drug Metab Toxicol; 2007 Aug; 3(4):609-20. PubMed ID: 17696810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.